PVCT
PROVECTUS BIOPHARMSstockOTC
EODNov 18, 2026
0.0437USD-0.046%(-0.00)61,190
PVCT Financials
In Q3 FY 2026 (ended ), PROVECTUS BIOPHARMS (PVCT) reported revenue of $0, net income of −$1.27M, operating cash flow of −$859.6K, and assets of $467.09K (filed ).
Loading financial statements…